Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.7K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.4K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

829
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
829
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

855
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
855
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

935
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
935
  1. ホーム
  3. 2型糖尿病における心不全と死亡率に対するダパグリフロジンの効果
  1. ホーム
  3. 2型糖尿病における心不全と死亡率に対するダパグリフロジンの効果

関連する実験動画

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.5K

2型糖尿病における心不全と死亡率に対するダパグリフロジンの効果

Eri T Kato1, Michael G Silverman2, Ofri Mosenzon3

  • 1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan (E.T.K.).

Circulation
|March 19, 2019

PubMed で要約を見る

まとめ
この要約は機械生成です。

ダパグリフロジンは,ナトリウム・グルコース・コトランスポーター2阻害剤で,2型糖尿病および心不全の患者に有益です. ダパグリフロジンは,すべての患者で心不全の入院を減少させ,エジェクション分数が減少した患者で心血管疾患による死亡と死亡率を改善しました.

キーワード:
糖尿病 糖尿病心不全死亡率ナトリウム・グルコース・トランスポーター2阻害剤

さらに関連する動画

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

555
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.0K

関連する実験動画

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.5K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

555
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.0K

科学分野:

  • 心臓病科
  • 内分泌学
  • 薬理学について

背景:

  • DECLARE- TIMI 58試験では,2型糖尿病患者のダパグリフロジンについて調査した.
  • SGLT2阻害剤は心臓血管に有益である.
  • SGLT2阻害剤の効果に対するエジェクション分数の影響は,以前は知られていなかった.

研究 の 目的:

  • 2型糖尿病患者におけるダパグリフロジンの臨床効果に対する基値左心室射出分数の効果を評価する.
  • 異なるEF層における心臓血管死亡と心臓不全入院 (HHF) の減少におけるダパグリフロジンの有効性を評価する.
  • すべての原因による死亡率に対するダパグリフロジンの影響をEFに基づいて分析する.

主な方法:

  • 基礎心不全 (HF) 状態とEFを含むDECLARE- TIMI 58試験データの分析
  • 減少したEF (HFrEF,EF < 45%),減少したEFのないHF,およびHFの歴のないHFに分類された患者.
  • 主なアウトカムには,心血管疾患による死亡/HHF,その構成要素,および全因死亡率の複合が含まれていた.

主要な成果:

  • ダパグリフロジンは,HFrEFのない患者と比較して,HFrEF (HR 0. 88; P相互作用=0. 046) を有意に減少させた.
  • HFrEFとHFrEF以外のグループにおいて,ダパグリフロジンによって心臓不全入院 (HHF) が減少した.
  • HFrEF (P相互作用 < 0. 02) の患者においてのみ,ダパグリフロジンは心血管疾患による死亡と全因死亡率を有意に減少させた.

    • 結論:

    • ダパグリフロジンは,2型糖尿病の患者,特にHFrEFの患者で臨床的に有意義な効果を示しています.
    • この研究は,EFに基づくダパグリフロジンの影響の差異を強調し,特別の治療アプローチを提案しています.
    • ダパグリフロジンによるSGLT2抑制は,EFスペクトル全体でHHFを減少させ,HFrEF患者の死亡率を改善します.